The discussion surrounding conditional reimbursement policies has grown more complicated in the current healthcare environment. Despite the uncertainty surrounding these policies’ efficacy and execution, we must investigate how we might proceed with them as we navigate this difficult terrain. [1]
In other words, a new technology is initially sponsored temporarily under a conditional reimbursement paradigm. Afterward, a second decision is made based on further information, with the option to either terminate funding if the technology does not provide enough value (a perceived loss, as the technology was previously financed and subsequently withdrawn) or continue funding in order to maintain the status quo. On the other hand, under a standard reimbursement paradigm, the choice is whether to support new technology, which might lead to either no gain at all or an improvement if funded.[1]
Systems that promote efficiency and quality have replaced traditional fee-for-service models, which pay providers according to the amount of services they provide. The entire cost, cost-effectiveness, and therapeutic benefit of new medications are often uncertain. Reimbursement with conditions is one way to deal with this uncertainty. New pharmacotherapies who have already received the approvals are the main candidates for conditional reimbursement. Conditional reimbursement rules provide financial rewards to healthcare providers who achieve predetermined performance targets. Although these guidelines aim to save costs and improve patient outcomes, these regulations have proven to be more difficult to implement.[1,2]
Critics claim that rules about conditional compensation may result in unforeseen outcomes, such as an excessive focus on quantity rather than quality, wherein clinicians give priority to fulfilling metrics rather than providing all-encompassing, patient-focused care. Furthermore, the added administrative work involved in monitoring and reporting results may cause funds to be diverted from providing direct patient care. The evidence is also ambiguous, and there is disagreement over what constitutes significant results, which causes differences in the formulation and application of policies. These policies also incite loss aversion, implying that greater incremental cost-effectiveness ratios (ICERs) are reasonable for current treatments than for novel treatments. This suggests that the decision-making procedure has a direct bearing on how a reimbursement decision turns out. The reassessment process appears to be a complicated and politically delicate procedure, according to the first experiences of countries implementing conditional reimbursement in practice. Gathering new information in practice tends to be difficult, and officials appear to take a somewhat passive approach to withdraw payment, most likely due to popular opposition to these decisions. Payers therefore require instruments to deal with these uncertainties in terms of both pricing and proof.[1,3]
Conditional reimbursement policy advocates think they have the key to revolutionizing healthcare delivery, notwithstanding these obstacles. They contend that by providing incentives for innovation and advancement, these models eventually help patients by reducing costs and improving health outcomes. Conditional reimbursement enables the collection of stronger evidence about the efficacy and economic viability of novel technologies. The level of proof required from manufacturers is raised by a conditional funding mechanism, particularly one that requires continual data creation in real-world contexts and feeds back into the HTA process. This strategy may be able to address the post-HTA negotiation’s delays and lack of transparency, particularly for novel new drugs whose assessments have been accelerated by the HTA and regulatory aspects of the reimbursement process.[1,4]
In order to effectively manage conditional reimbursement policies, a comprehensive plan including multiple crucial tactics is required. Policymakers should be aware of this possible problem when using conditional reimbursement as a tool for policy, as the decision-making process directly affects the outcome of a reimbursement decision. In order to jointly establish policies that support common objectives of enhancing patient outcomes and cutting costs, it is important to involve stakeholders from all corners of the healthcare spectrum, including payers, providers, lawmakers, and patients. To guarantee that policies continue to be applicable and successful, mechanisms for ongoing review and modification should be put in place. This will allow for ongoing policy evolution based on empirical data. In addition, healthcare practitioners need sufficient assistance and training to comprehend conditional reimbursement rules and use them successfully. Any technological obstacles that could prevent compliance must also be addressed.[1]
Navigating conditional reimbursement systems at the intersection of value-based and traditional healthcare calls for careful thought, dedication to cooperation, and adaptability. By taking a balanced approach that promotes patient outcomes, reduces administrative expenses, and fosters innovation, we can advance a plan that will benefit healthcare providers as well as the communities they serve. The road ahead is unknown, but by carefully drafting policies and emphasizing evidence-based decision-making, we may get closer to having a healthcare system that offers both value and quality.
Become A Certified HEOR Professional – Enrol yourself here!
References:
- Van de Wetering EJ, van Exel J, Brouwer WB. The challenge of conditional reimbursement: stopping reimbursement can be more difficult than not starting in the first place! Value Health. 2017;20(1):118-125. doi:10.1016/j.jval.2016.09.001.
- Pharmaceutical Pricing Board. Conditional reimbursement: guide for applicants. Available from: https://www.hila.fi/content/uploads/2023/01/Ehdollinen-korvattavuus_ohje-hakijoille_29.3.2023_EN.pdf.
- Mortimer D, Li JJ, Watts J, Harris A. Breaking up is hard to do: the economic impact of provisional funding contingent upon evidence development. Health Econ Policy Law. 2011;6:509-27.
- Glennie J, Villalba E, Wheatley-Price P. Closing the gaps to timely patient access: perspectives on conditional funding models. Curr Oncol. 2022;29(2):981–988. doi:10.3390/curroncol29020083.
Traditionally, the pharmaceutical industry has always been dependent upon the ‘push’ strategy for successful market access for products. The drug approval process, involving submission of data on efficacy, safety, and tolerability to the regulatory agencies, used to be simple; which ended with the drug being marketed to the targeted physicians and dispensed by pharmacies post approval. Thus, this whole process involved a limited set of stakeholders, viz. physicians, regulatory agencies, and pharmacies. Conversely, over the years, the market access landscape has evolved primarily due to two factors: (1)
Every country exercises strict control on medicines’ market access. Typically, this requires successful completion and adequate presentation of results from phase I through phase III clinical trials, bringing forward the findings of medicine’s safety and efficacy. The USFDA approves approximately 40 new medicines for the US market each year through this process. (1) In India, this number is more than 100 new medicines annually; however, there is not enough published evidence on submitted applications or summaries of approved medicines. Therefore, concerns are being raised about the safety and efficacy around medicine approvals in India in the absence of appropriate clinical trials. (2,3)